Moderna joins the Association of the British Pharmaceutical Industry

Moderna becomes the latest member of the Association of the British Pharmaceutical Industry (ABPI), deepening the company’s UK connections.

Moderna has become the newest member of the UK’s leading pharmaceutical industry body, building on the wider long-term commitment by the American-based company to expand its footprint and investment in the UK.

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has high ambitions for rapid global growth. Key to these ambitions will be a new state-of-the-art vaccine research, development and manufacturing facility in the UK, creating valuable new jobs and building on the strength of the UK’s life sciences ecosystem.

Founded in 2010 and now employing over 3900 people globally and around 30 in the UK, Moderna is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions.

The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world’s largest, most innovative, and most successful pharmaceutical firms. All members sign up to adhere to the high standard of conduct captured by the ABPI Code of Practice.

Darius Hughes, UK General Manager, Moderna, said:

“We are delighted to join the ABPI – this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.

“Moderna is committed to delivering the greatest possible impact to people through mRNA medicines. We look forward to working with the ABPI and our fellow member companies to build on the already strong UK environment for science and innovation.”

Richard Torbett, Chief Executive, ABPI, said:

“I’m delighted to welcome Moderna into membership as a world-leading pharmaceutical company that can help bring the UK closer to realising its ambitions to be a leading global centre for life sciences.

“With Moderna’s help we will be in an even stronger position to make the UK the best place in the world to research, develop and use new medicines and vaccines.”